News

The company will produce ADI-PEG 20 products and targets an annual production value of around $2bn, news.cens.com reported. Polaris developed ADI-PEG 20 drug for the treatment of cancers.

Martino served at a cancer therapeutics company – Sonus Pharmaceuticals as president and CEO from 1999 to 2008 where he developed company’s lead cancer therapeutic through a pivotal

The study involved 132,000 patients who were placed into categories to compare levels of vitamin D: low (less than 20 nanograms per decilter), low/normal (21-40 ng/dl), normal (41-80

Cenix conducts contract research and develops technology for RNA interference (RNAi), miRNA modulation and high content phenotyping to accelerate target discovery, target validation, and the non-clinical development of

Biosimilars are drugs whose effects are similar to those of biopharmaceuticals and are sold by a different manufacturer once the original drugs’ patent expires, pharmalive.com reported. The joint

Under the agreement, both the companies will boost the clinical development besides increasing productivity and cost effectiveness. UCB will receive the benefits of PAREXEL’s clinical processes through all

Menerba, an oral, estrogen receptor beta (ER-b) selective drug candidate is developed to treat vasomotor symptoms (hot flashes) associated with menopause, which is manufactured from botanical sources. The

The first patent covers a class of compounds that combine elements of diketopiperazines and methylphenidate derivatives, while the second patent is directed to novel derivatives of methylphenidate (Ritalin).

The company recently filed its first provisional patent application for use of anti-adhesion molecule therapies to treat FIV infections, and has identified three candidate antibodies that are likely